Meningitis Vaccines Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Meningitis Vaccines Market Trends and Insights

Expansion Of Adolescent And Young-Adult Immunization Programs

Adolescent and young-adult immunization schedules remained a key demand driver in the meningitis vaccines market. The CDC recommended MenACWY vaccination for children aged 11 to 12 years, followed by a booster at age 16. By mid-2024, 26 U.S. states required MenACWY vaccination evidence for college or university entry, supporting recurring demand independent of outbreaks. U.S. invasive meningococcal disease cases increased from 312 in 2022 to 438 in 2023 and 477 in 2024, increasing focus on booster coverage.^{[1]Centers for Disease Control and Prevention, “Increase in Invasive Serogroup Y Meningococcal Disease in the United States,” CDC Health Alert Network Advisory, cdc.gov} The ACIP review of MenACWY at ages 11 to 12 years and MenABCWY at age 16 could reduce injections and support demand for higher-value combination products.

Increasing Adoption Of MenB And MenABCWY Vaccines

The availability of two MenABCWY vaccines in the U.S. formulary strengthened competition in the meningitis vaccines market. The FDA approved GSK’s Penmenvy on February 14, 2025. On April 16, 2025, ACIP recommended Penmenvy for individuals aged 16 to 23 years through shared clinical decision-making and for risk-based groups aged 10 years and older. Fewer than 13% of eligible U.S. adolescents completed the two-dose MenB series, creating a coverage gap for combination vaccines to address. GSK reported that its MenB-4C component accounted for three of every four MenB doses administered in U.S. channels during 2024, while only 54% of surveyed physicians knew of the shared clinical decision-making recommendation.

Introduction Of Pentavalent Vaccines In The African Meningitis Belt

MenFive, also known as Men5CV, protects serogroups A, C, W, Y, and X, expanding prevention options in the African meningitis belt. The Serum Institute of India and PATH developed the vaccine over 13 years with U.K. government support. The vaccine received WHO prequalification in July 2023, and eligibility was expanded to infants aged 9 months and older in March 2024. Nigeria first deployed Men5CV in March 2024 and vaccinated more than 1 million people during a serogroup C outbreak. In April 2025, Nigeria received 1.5 million additional doses from the Gavi-funded ICG stockpile for a concurrent serogroup C and W outbreak that caused more than 70 deaths across 23 states; Niger’s 2025 campaign also demonstrated the value of storage at 40°C for up to 28 days.

Greater Public-Health Focus On Outbreak Prevention And Travel Immunization

Public health initiatives expanded demand beyond countries that traditionally used meningococcal vaccines most widely. In April 2025, the WHO published its first clinical guidelines for meningitis diagnosis, treatment, and care, providing member states with a common framework for surveillance and clinical response.^{[2]World Health Organization, “WHO Guidelines on Meningitis Diagnosis, Treatment and Care,” World Health Organization, who.int} Saudi Arabia requires MenACWY conjugate vaccination for Hajj and Umrah pilgrims, sustaining annual demand among travelers from South and Southeast Asia. The serogroup Y ST-1466 strain increased focus on adult risk because cases often presented as bacteremia rather than meningitis. This trend supported broader consideration of quadrivalent and pentavalent vaccines, while MenB programs could gain support if research confirmed protection against gonorrhea.

Low Disease Incidence And Challenging Vaccine Cost-Effectiveness

Low disease incidence in high-income countries limited the business case for expanding universal vaccination programs in the meningitis vaccines market. In the United States, incidence ranged from 0.10 to 0.11 cases per 100,000 people annually. Despite 477 reported U.S. cases in 2024, the disease burden remained lower than that of conditions commonly targeted through universal adult vaccination. ACIP economic modeling found that replacing MenACWY vaccination with Penmenvy costs USD 11.3 million per quality-adjusted life year gained. This estimate exceeded common public-payer thresholds and restricted broader MenB vaccination recommendations. Suppliers relied on provider education and advocacy in the absence of payer mandates, creating challenges for smaller companies without established relationships with public health institutions.

Short Duration Of Protection And Requirement For Booster Doses

Waning immunity complicated vaccination program planning, as additional doses increased theoretical demand but reduced real-world completion rates. In April 2025, ACIP changed the recommended MenB-4C dosing interval from at least 1 month to at least 6 months after reviewing evidence of stronger immune responses at the longer interval.^{[3]“Potential Use of Neisseria meningitidis Serogroup B Vaccines Against Gonorrhoeae,” Journal of the International AIDS Society, ovid.com} Two-year persistence data showed similar seroprotective titers after two doses of Penmenvy and control vaccines, although evidence certainty remained low among healthy individuals. Observational evidence suggested that MenB-4C protection against gonorrhea began to decline 36 months after vaccination. In the meningitis belt, follow-up surveillance and potential revaccination increased the cost and logistical pressure on limited program budgets. 

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type: Quadrivalent Formulations Retain Their Established Position

Quadrivalent formulations held 53.45% of the meningitis vaccines market share in 2025. Their position reflects established adolescent immunization schedules in North America and Europe, where providers and public programs are familiar with MenACWY products. MenQuadfi and Menveo support demand through broad U.S. age indications, covering infant, pediatric, adolescent, and adult vaccination. Monovalent products, including MenAfriVac and MenFive in Africa, depend primarily on Gavi funding and public tenders. The others category includes emerging combination products and polysaccharide vaccines used in lower-income settings transitioning to conjugate vaccination.

Bivalent formulations are forecast to register the highest CAGR of 8.78% through 2031. MenB and MenAC products support growth through national programs in the United Kingdom and state programs in Australia. The United Kingdom's established MenB-4C program provides a recurring demand base. As of December 2025, six randomized controlled trials were evaluating 4CMenB efficacy against gonorrhea, with most results expected by the end of 2026. These results could influence future program decisions but would not replace the established meningococcal indication.

By Brand: Bexsero Leads While Menveo Has The Highest Growth Rate

Bexsero accounted for 34.56% of the meningitis vaccines market share in 2025. Its position reflects adoption across 18 national immunization programs and the distribution of more than 110 million doses globally since 2015. Penmenvy combines Bexsero's MenB-4C antigen components with Menveo's ACWY coverage in a single product. GSK reported that its MenB-4C component accounted for three out of every four MenB doses administered through U.S. channels in 2024. This installed base supports GSK's position in combination vaccination.

Menveo is forecast to grow at a CAGR of 9.44% through 2031, the highest rate among the brands included in the estimates. As the MenACWY component of Penmenvy, it benefits from standalone demand and combination vaccine adoption. Penbraya and Penmenvy are positioned to benefit if adolescent schedules increasingly use pentavalent products. MenFive and MenAfriVac serve public-sector markets in the African meningitis belt, with prices benchmarked at or below USD 3 per dose. Nimenrix, MenQuadfi, and other branded vaccines compete primarily in private channels across Europe and Asia.

By Age Group: Children Provide The Largest Base And Infants Drive Growth

Children aged 2 to 11 years represented 58.54% of the meningitis vaccines market share in 2025. Pediatric schedules in North America and Europe support demand through routine vaccination, school-entry requirements, travel vaccination, and outbreak response. This age group includes both primary vaccination and preadolescent catch-up activity, supporting steady public and private purchasing volumes. Adolescents aged 12 to 17 years remain important, as MenACWY boosters and MenB vaccination initiation are concentrated during this period. College-entry requirements further support vaccination completion.

Infants aged 0 to 2 years are forecast to grow at a CAGR of 10.25% through 2031. The FDA approved MenQuadfi in May 2025 for children as young as 6 weeks, supported by three late-stage studies involving more than 6,000 participants aged 6 weeks to 19 months. The European Commission is expected to approve MenQuadfi for infants aged 6 weeks and older on August 4, 2026. This development would place Sanofi in direct competition with Menveo and Nimenrix for early-life national immunization tenders. ECDC surveillance data identified infants under 1 year as the group with the highest incidence of invasive meningococcal disease in the EU and EEA.

By Serotype: Serogroup Y Has The Largest Share And Serogroup B Expands Fastest

Serogroup Y held 32.98% of the meningitis vaccines market share in 2025. Its position reflects the wider circulation of the ST-1466 and ST-23 clonal complexes. The CDC reported that ST-1466 accounted for 68% of U.S. serogroup Y cases in 2023 and identified atypical bacteremia presentations and an 18% mortality rate among assessed cases. In Hubei Province, China, the first recorded serogroup Y outbreak in 2024 was linked to the ST-1655 strain of the ST-23 complex. The study reported a 12.2% carriage rate among classmates, while China's national immunization schedule covered serogroups A and C rather than serogroup Y.

Serogroup B is forecast to grow at a CAGR of 8.25% through 2031. Growth is supported by the expansion of MenB programs in countries where it remains the leading cause of invasive disease. In England, serogroup B caused 313 of 372 laboratory-confirmed cases during the 2024-2025 epidemiological year, up 4.3% from 300 cases in 2023-2024. A systematic review and meta-analysis found that MenB-4C had a pooled effectiveness of 32.4% against gonorrhea, with a 95% confidence interval of 26.2% to 38.7%, across eight peer-reviewed studies. This evidence could influence future funding discussions in the United Kingdom, Australia, and the United States.

By Sales Channel: Private Sales Lead While Public Procurement Grows Faster

Private sales held 64.73% of the meningitis vaccines market share in 2025. This channel benefits from demand for MenB and MenABCWY products in high-income settings, where insurance coverage varies. Commercial U.S. prices for MenB vaccines ranged from USD 150 to USD 180 per dose in private channels, supporting a high-value revenue base despite lower volumes than public programs. Private demand is also significant, where optional vaccination depends on provider recommendations or travel requirements. In China, private-market consumers use CanSino's Menhycia quadrivalent conjugate vaccine, while the national program funds polysaccharide MenA and MenAC vaccines.

Public sales are forecast to grow at a CAGR of 8.65% through 2031. Gavi-funded procurement of MenFive in the African meningitis belt supports growth, while the U.S. Vaccines for Children program includes Penbraya and Penmenvy for eligible pediatric populations. National program expansion in middle-income Asia-Pacific countries provides another avenue for public procurement. CanSino expanded Menhycia's approved age range to children aged 3 months to 6 years in February 2026. China's NMPA accepted a supplemental application in July 2026 to extend the indication to individuals aged 3 months to 17 years.

Geography Analysis

North America held 45.67% of the meningitis vaccines market share in 2025, supported by the U.S. adolescent immunization schedule, combined vaccine approvals, and MenQuadfi’s broader infant indication. U.S. cases increased from 208 in 2021 to 477 in 2024, highlighting coverage gaps among adults and immunocompromised individuals. In Quebec, the disease pattern shifted from predominantly serogroup B to serogroup Y after 2015, with 80.9% of MenY cases associated with the ST-23 clonal complex. Mexico’s private healthcare and travel vaccination demand created additional opportunities, while U.S. FDA and ACIP decisions continued to influence immunization schedule discussions in other countries.

Europe remained a significant source of public procurement for the meningitis vaccines market. The United Kingdom’s routine infant MenB-4C program and MenACWY adolescent schedule supported stable demand. The UK Health Security Agency reported 372 invasive meningococcal disease cases in 2024–2025, compared with 340 cases in 2023–2024, while MenW cases increased from 17 to 43. France, Germany, and Spain accounted for 57% of cases in the cited EU and EEA surveillance report, with serogroup B identified as the leading cause among individuals under 65 years.

Asia-Pacific is forecast to grow at a CAGR of 8.94% through 2031. China’s immunization program continued to rely on polysaccharide serogroup A and C vaccines, leaving adolescents without routine protection against serogroups Y and W, while the 2024 Hubei school outbreak increased attention to this gap. CanSino’s Menhycia offered a quadrivalent private-market option and expanded its approved age indications in 2026. South Korea launched MenQuadfi through SK Bioscience and Sanofi in January 2026 for infants aged 6 weeks to 24 months and other approved groups. The Middle East and Africa combined premium private travel vaccination demand in GCC countries with public procurement in the African meningitis belt, while South America remained at an earlier stage of quadrivalent adoption, led by Brazil’s meningococcal C program.